Novartis Faces Legal Revival Over Gilenya Kickback Claims
Novartis is under scrutiny as a U.S. court revives a whistleblower lawsuit alleging kickbacks in promoting its MS drug, Gilenya. Impact on reputation and stock price likely.
Novartis is facing revived legal claims for allegedly using kickbacks to promote Gilenya, impacting its reputation and market performance.